Day: May 1, 2023

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...

Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

The Canadian Dermatology Association launches its month-long National Sun Awareness Campaign, and its partnership and support of Melanoma Canada’s Mole Mobile Skin Cancer Screening Unit

OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) launches its month-long Sun Awareness Month campaign, urging...

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...

error: Content is protected !!